Aging vs Neurodegeneration: Mechanistic Comparison Matrix

Aging vs Neurodegeneration: Mechanistic Comparison Matrix

Introduction

Distinguishing normal brain aging from neurodegenerative disease remains one of the fundamental challenges in neuroscience. While aging represents the single greatest risk factor for neurodegenerative diseases, the mechanistic boundaries between physiological aging and pathological neurodegeneration are often blurred. This page provides a detailed comparison matrix to clarify which molecular and cellular changes represent normal aging processes versus disease-specific pathological mechanisms. [@selkoe2002]

Understanding these distinctions is critical for developing therapeutic interventions. If we can identify the specific mechanisms that transform normal aging into Alzheimer's Disease (AD) or Parkinson's Disease (PD), we may be able to develop targeted interventions to prevent or delay disease onset [1](https://pubmed.ncbi.nlm.nih.gov/24353158/).

Overview Comparison Matrix

Aging vs Neurodegeneration: Mechanistic Comparison Matrix

Introduction

Distinguishing normal brain aging from neurodegenerative disease remains one of the fundamental challenges in neuroscience. While aging represents the single greatest risk factor for neurodegenerative diseases, the mechanistic boundaries between physiological aging and pathological neurodegeneration are often blurred. This page provides a detailed comparison matrix to clarify which molecular and cellular changes represent normal aging processes versus disease-specific pathological mechanisms. [@selkoe2002]

Understanding these distinctions is critical for developing therapeutic interventions. If we can identify the specific mechanisms that transform normal aging into Alzheimer's Disease (AD) or Parkinson's Disease (PD), we may be able to develop targeted interventions to prevent or delay disease onset [1](https://pubmed.ncbi.nlm.nih.gov/24353158/).

Overview Comparison Matrix

| Feature | Normal Brain Aging | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | HD |
|---------|-------------------|---------------------|---------------------|-----|-----|-----|
| Onset | Gradual, decades | Typically >65 years | Typically >60 years | 40-60 years | 45-65 years | 30-50 years |
| Progression | Linear, slow | Exponential decline | Gradual with plateaus | Rapid (2-5 years) | Variable | Slow (15-20 years) |
| Cognitive Impact | Mild forgetfulness | Progressive dementia | Later cognitive decline | Usually preserved | Primary symptom | Progressive dementia |
| Motor Impact | Minor slowing | Late-stage impairment | Primary symptom | Primary symptom | Rare | Early chorea, later rigidity |
| Neuropathology | Minimal protein accumulation | Aβ plaques, tau tangles | Lewy bodies (α-syn) | TDP-43 inclusions | TDP-43 or tau | Mutant huntingtin aggregates |
| Neuronal Loss | ~10% over lifetime | 20-50% in affected regions | 50-70% in substantia nigra | 80-90% in motor neurons | 30-60% in frontal/temporal | 50-80% in striatum |
| Disease-Modifying Treatment | N/A | Lecanemab, donanemab | None approved | Riluzole, edaravone | None | None |

Mechanistic Comparison Matrix

Mitochondrial Dysfunction

| Feature | Normal Aging | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | HD |
|---------|-------------|-------------------|-------------------|-----|-----|-----|
| ATP Decline | 10-20% decrease | 40-60% decline | 30-50% decline | 40-70% decline | 30-50% decline | 40-60% decline |
| Complex Affected | All complexes mildly reduced | Complex IV (cytochrome c oxidase) | Complex I severely deficient | All complexes | Variable | Complex I and II |
| ROS Production | Moderate increase | High (amplified by Aβ) | Very high (dopamine auto-oxidation) | Very high | Moderate-high | Very high |
| mtDNA Mutations | Accumulation with age | Accelerated accumulation | Mitochondrial DNA haplogroups affect risk | Accelerated | Variable | CAG repeat-related |
| Mitophagy | 20-30% decline | Severely impaired | PINK1/Parkin pathway disrupted | Impaired | Impaired | Impaired |
| Calcium Buffering | Reduced efficiency | Severely impaired | Moderately impaired | Impaired | Variable | Impaired |

Normal brain aging involves a gradual decline in mitochondrial function across all complexes, with approximately 10-20% reduction in ATP production by age 70 [2](https://pubmed.ncbi.nlm.nih.gov/29346542/). In contrast, neurodegenerative diseases show severe, selective complex deficiencies. Parkinson's Disease is particularly characterized by complex I deficiency, which is thought to result from genetic (PINK1, PARKIN mutations) and environmental (MPTP, pesticides) factors [3](https://pubmed.ncbi.nlm.nih.gov/16637055/). Alzheimer's Disease shows complex IV impairment and a bidirectional relationship with amyloid-beta, where Aβ localizes to mitochondria and exacerbates dysfunction while mitochondrial dysfunction promotes Aβ production [4](https://pubmed.ncbi.nlm.nih.gov/18614023/).

ALS shows severe mitochondrial dysfunction across all complexes, with particular impairment of complex I and IV. Mutations in [SOD1](/genes/sod1), [C9orf72](/genes/c9orf72), and TDP-43 all directly impact mitochondrial function. FTD shows variable mitochondrial impairment depending on the subtype—TDP-43 cases show mitochondrial dysfunction in frontal neurons, while tau cases show different patterns. [HD](/diseases/huntingtons) shows early and severe mitochondrial impairment, with complex I and II particularly affected, and this is thought to be driven by mutant huntingtin's direct interaction with mitochondria.

Neuroinflammation

| Feature | Normal Aging | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | HD |
|---------|-------------|-------------------|-------------------|-----|-----|-----|
| Microglial State | Primed, hyper-ramified | DAM (Disease-Associated) | Reactive, amoeboid | Highly reactive | Reactive | Highly reactive |
| Baseline Cytokines | Mild elevation (IL-6, TNF-α) | High elevation | High elevation | Very high (IL-6, IL-1β) | Moderate-high | High |
| NF-κB Activation | Low chronic | Persistent, strong | Persistent, strong | Strong | Variable | Persistent |
| NLRP3 Inflammasome | Moderate activation | Strong activation | Strong activation | Strong | Moderate | Strong |
| TREM2 Expression | Reduced | Loss-of-function risk | Altered expression | Altered | Variable | Reduced |
| Blood-Brain Barrier | Mild leakiness | Compromised | Compromised | Compromised | Variable | Compromised |

The concept of "inflammaging" describes the chronic, low-grade inflammation that characterizes the aging brain. This involves microglial priming—a state where microglia adopt a hyper-ramified morphology with elevated baseline activation of pattern recognition receptors [5](https://pubmed.ncbi.nlm.nih.gov/29395814/). In neurodegenerative diseases, this primed state becomes pathological. In AD, the NLRP3 inflammasome is strongly activated by amyloid-beta oligomers, driving chronic IL-1β release that impairs amyloid clearance while promoting tau pathology spread [6](https://pubmed.ncbi.nlm.nih.gov/25610011/). In PD, microglial activation in the substantia nigra is particularly pronounced, driven by neuromelanin release and α-synuclein aggregation [7](https://pubmed.ncbi.nlm.nih.gov/19819166/).

ALS shows the most severe neuroinflammation, with microglial activation beginning early and contributing to disease progression through toxic SASP factors. FTD shows region-specific inflammation depending on whether TDP-43 or tau pathology predominates. HD shows early microglial activation in the striatum, driven by mutant huntingtin expression in microglia themselves.

Protein Homeostasis

| Feature | Normal Aging | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | HD |
|---------|-------------|-------------------|-------------------|-----|-----|-----|
| Proteasome Activity | 30-50% decline | Severely impaired | Impaired | Severely impaired | Impaired | Impaired |
| Autophagy Flux | Reduced | Severely impaired | Severely impaired (mitophagy) | Impaired | Impaired | Severely impaired |
| Chaperone Function | 20-40% decline | Hsp70 impaired | Hsp70 impaired | Impaired | Impaired | Impaired |
| Aggregate Clearance | Mostly effective | Failed (plaques, tangles) | Failed (Lewy bodies) | Failed (TDP-43 inclusions) | Failed (TDP-43 or tau) | Failed (mHtt aggregates) |
| Specific Proteins | Generalized decline | Aβ, tau accumulation | α-synuclein accumulation | TDP-43 accumulation | TDP-43 or tau | Mutant huntingtin |
| CMA Activity | Declined | Reduced | Severely reduced | Reduced | Reduced | Severely reduced |

Protein homeostasis (proteostasis) decline is a hallmark of both aging and neurodegeneration, but the outcome differs critically. In normal aging, the proteostasis network is reduced but generally maintains effective clearance of misfolded proteins [8](https://pubmed.ncbi.nlm.nih.gov/23455629/). In neurodegeneration, this system fails catastrophically, leading to the accumulation of disease-specific protein aggregates. The autophagy-lysosome pathway shows particular vulnerability in PD, with chaperone-mediated autophagy (CMA) being severely impaired. This is especially significant because α-synuclein is normally degraded via CMA, and its accumulation further inhibits CMA, creating a vicious cycle [9](https://pubmed.ncbi.nlm.nih.gov/19446878/).

ALS shows [TDP-43](/proteins/tdp-43-protein) aggregates in 95% of cases, with impaired autophagy and proteasome function directly contributing to aggregate accumulation. FTD shows either TDP-43 (50% of cases) or tau (50% of cases) aggregates, with different proteostasis mechanisms affected depending on the subtype. HD shows early impairment of autophagy, with mutant huntingtin directly impairing autophagosome formation and cargo recognition.

Synaptic Changes

| Feature | Normal Aging | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | HD |
|---------|-------------|-------------------|-------------------|-----|-----|-----|
| Spine Density | 10-20% reduction | 25-50% reduction | 20-40% reduction | 30-50% reduction | 20-40% reduction | 30-50% reduction |
| LTP Impairment | Mild | Severe | Moderate | Variable | Moderate-severe | Severe |
| Neurotransmitter Decline | Mild (all systems) | Acetylcholine major | Dopamine major | Glutamate (excitotoxicity) | Variable | GABA and dopamine |
| Pre-synaptic Markers | Mild reduction | Severely reduced | Severely reduced | Reduced | Reduced | Severely reduced |
| Postsynaptic Density | Preserved | Disrupted | Disrupted | Disrupted | Disrupted | Disrupted |
| BDNF Levels | 20-30% decline | 50%+ decline | Reduced | Reduced | Reduced | Severely reduced |

Synaptic dysfunction represents a common thread between aging and neurodegeneration, but the magnitude differs substantially. Normal aging involves mild synaptic changes—approximately 10-20% reduction in dendritic spine density in the hippocampus and prefrontal cortex [10](https://pubmed.ncbi.nlm.nih.gov/25475137/). These changes correlate with mild cognitive impairment but do not progress to catastrophic loss. In AD, synaptic loss is the strongest correlate of cognitive decline, with 25-50% reduction in spine density in affected regions. The loss of excitatory synapses, particularly those containing PSD-95, occurs early and progresses with disease severity [11](https://pubmed.ncbi.nlm.nih.gov/19219065/). In PD, synaptic changes are most pronounced in dopaminergic terminals in the striatum, where dopamine release is reduced even before significant neuronal loss is detectable [12](https://pubmed.ncbi.nlm.nih.gov/23587861/).

In ALS, synaptic dysfunction begins at the neuromuscular junction (NMJ) and spreads to central synapses, with excitotoxicity playing a major role. FTD shows synaptic loss in frontal and temporal regions corresponding to the affected brain networks. HD shows early synaptic dysfunction in striatal medium spiny neurons, with both pre-synaptic and postsynaptic deficits.

Cellular Senescence

| Feature | Normal Aging | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | HD |
|---------|-------------|-------------------|-------------------|-----|-----|-----|
| p16^INK4a^ Expression | Low-level accumulation | High in neurons and glia | High in neurons and glia | High in motor neurons | High in frontal neurons | High in striatal neurons |
| SA-β-gal Activity | Moderate increase | High in microglia | High in microglia | High in glia | High in glia | High in neurons |
| SASP Factors | Low-moderate | High (amplified) | High (amplified) | High | High | High |
| Neuronal Senescence | Rare | Common in affected regions | Common in substantia nigra | Common in motor neurons | Common in frontal cortex | Common in striatum |
| SASP Clearance | Effective | Impaired | Impaired | Impaired | Impaired | Impaired |
| Senolytic Sensitivity | Moderate | High | High | High | High | High |

Cellular senescence is increasingly recognized as a contributor to both aging and neurodegeneration. In normal aging, senescent cells accumulate slowly, contributing to chronic inflammation through the senescence-associated secretory phenotype (SASP) [13](https://pubmed.ncbi.nlm.nih.gov/29108004/). In neurodegenerative diseases, neuronal senescence appears to be accelerated and exaggerated. In AD, tau pathology correlates with p16^INK4a^ expression in neurons, suggesting a direct link between tau aggregation and cellular senescence [14](https://pubmed.ncbi.nlm.nih.gov/32084332/). In PD, the substantia nigra shows particularly high levels of senescent microglia, which may contribute to the selective vulnerability of dopaminergic neurons [15](https://pubmed.ncbi.nlm.nih.gov/32947582/).

In ALS, TDP-43 pathology in motor neurons is associated with p16^INK4a^ expression and cellular senescence markers. Senescent astrocytes and microglia surrounding motor neurons contribute to toxic SASP signaling that drives disease progression. In FTD, frontotemporal neurons with TDP-43 or tau pathology show elevated senescence markers, particularly in the TDP-43 cases. In HD, mutant huntingtin drives cellular senescence in striatal neurons through multiple mechanisms including mitochondrial dysfunction, oxidative stress, and impaired autophagy.

Mechanistic Divergence: Aging to Neurodegeneration

This diagram illustrates how normal aging processes can diverge into either AD, PD, ALS, FTD, or HD pathology. Common aging mechanisms (left) can branch into disease-specific pathways depending on genetic susceptibility, environmental exposures, and additional factors. For AD, the key divergence point involves amyloid-beta metabolism and the interaction between Abeta and mitochondrial dysfunction. For PD, the critical branch point involves mitochondrial complex I integrity and the selective vulnerability of substantia nigra pars compacta neurons. For ALS, RNA metabolism disruption combined with TDP-43 mislocalization represents the critical divergence. For FTD, progranulin haploinsufficiency leads to TDP-43 dysfunction and frontotemporal degeneration. For HD, the CAG repeat expansion drives mutant huntingtin aggregation and transcriptional dysregulation.

Shared Mechanisms vs Disease-Specific Mechanisms

Shared Between Aging and Neurodegeneration

• Mitochondrial dysfunction (varying severity)
• Neuroinflammation/inflammaging
• Proteostasis decline
• Synaptic changes
• Cellular senescence
• Epigenetic alterations
• Vascular changes

Disease-Specific Mechanisms

Alzheimer's Disease:

• Amyloid precursor protein (APP) processing dysregulation
• Amyloid-beta (Aβ42) aggregation
• Tau hyperphosphorylation and spreading
• Neurofibrillary tangle formation
• Acetylcholine system degeneration
• APOE ε4-driven pathology amplification

• α-synuclein misfolding and aggregation
• Lewy body formation
• Mitochondrial complex I deficiency
• PINK1/Parkin mitophagy pathway disruption
• Substantia nigra pars compacta selectivity
• Dopaminergic system degeneration
• [GBA](/genes/gba)-associated lysosomal dysfunction

• [TDP-43](/proteins/tdp-43-protein) proteinopathy (95% of cases)
• [SOD1](/proteins/sod1) mutations and toxic gain-of-function
• [C9orf72](/genes/c9orf72) hexanucleotide repeat expansion
• RNA metabolism disruption
• Excitotoxicity (glutamate)
• NMJ denervation
• Respiratory failure (cause of death)

• TDP-43 proteinopathy (50% of cases)
• Tau pathology (50% of cases)
• Progranulin haploinsufficiency
• C9orf72 hexanucleotide repeat expansion
• Behavioural variant (bvFTD) vs language variants
• Ubiquitin-positive inclusions

• Mutant huntingtin (mHtt) aggregation
• CAG repeat expansion (≥36 repeats = pathogenic)
• Transcriptional dysregulation
• Loss of brain-derived neurotrophic factor (BDNF)
• Striatal neuron selectivity
• Chorea (early) → parkinsonism (late)

Therapeutic Implications

Understanding the distinction between aging and neurodegeneration has critical therapeutic implications:

| Approach | Target Aging | Target Neurodegeneration |
|----------|-------------|------------------------|
| Senolytics | Remove senescent cells | Remove disease-associated senescence |
| Anti-inflammatory | Reduce inflammaging | Dampen pathological inflammation |
| Mitochondrial | Support general function | Target complex I (PD), Aβ-mito interaction (AD) |
| Proteostasis | Enhance clearance capacity | Disease-specific aggregate clearance |
| Synaptic | Preserve function | Rebuild lost synapses |

Clinical Trials

Several clinical trials target mechanisms at the intersection of aging and neurodegeneration:

| Trial ID | Intervention | Target | Phase | Status | Outcome |
|----------|--------------|--------|-------|--------|---------|
| NCT03015311 | Pioglitazone | Neuroinflammation, mitochondrial function | Phase 2 | Completed | Biomarker changes observed |
| NCT02957569 | Dasatinib + Quercetin | Senolytics (dasatinib + quercetin) | Phase 1/2 | Recruiting | Targeting senescent cells |
| NCT04063124 | Rapamycin (mTOR inhibition) | Proteostasis, autophagy | Phase 2 | Active | Evaluating cognitive outcomes |
| NCT04242988 | Metformin | Mitochondrial function, cellular metabolism | Phase 3 | Recruiting | Cognitive outcomes in MCI/AD |
| NCT03820778 | NAD+ precursors (NR) | Cellular metabolism, mitochondrial function | Phase 1 | Completed | Safe, biomarker changes |
| NCT03450004 | TREM2 agonist | Microglial activation (AD) | Phase 1 | Recruiting | Targeting neuroinflammation |
| NCT05048455 | Saracatinib (Fyn inhibitor) | Synaptic dysfunction, tau toxicity | Phase 2 | Completed | Mixed results |
| NCT04150302 | Ceramide analog | Lipid metabolism, proteostasis | Phase 1 | Recruiting | Targeting cellular stress |
| NCT05830337 | Cerebrolysin | Neuroprotection, neurotrophic factors | Phase 2 | Active | Cerebrovascular protection |
| NCT03430072 | Endoxifen | Protein aggregation (tamoxifen derivative) | Phase 1 | Completed | Targeting amyloid/tau |
| NCT04662337 | Rapamycin (mTOR inhibitor) | Aging/AD | Phase 2 | Recruiting | Evaluating mTOR inhibition |
| NCT04412421 | Dasatinib + Quercetin | Senolytics | Phase 1/2 | Completed | Clearing senescent cells |
| NCT05538530 | NMN (Nicotinamide mononucleotide) | NAD+ decline | Phase 1 | Recruiting | Addresses age-related NAD+ loss |

Key Findings

• Senolytic trials (NCT02957569): Targeting senescent cells using dasatinib plus quercetin shows safety in humans; trials ongoing for AD and PD
• TREM2 agonists (NCT03450004): Novel approach to modulate microglial function in AD; first-in-human data expected soon
• NAD+ precursors (NCT03820778): Nicotinamide riboside (NR) supplementation safely increases NAD+ levels and shows promise for mitochondrial function
• Metformin (NCT04242988): Large-scale trial in MCI/AD targeting cellular metabolism and inflammation
• mTOR inhibition (NCT04662337): Rapamycin and analogs show promise in preclinical models for cognitive outcomes

Emerging Approaches

• mTOR inhibition: Rapamycin and rapamycin analogs to enhance autophagy and proteostasis
• Senostatic therapies: Drugs that suppress the senescence-associated secretory phenotype (SASP) without killing senescent cells
• NAD+ Boosters: NMN, NR supplements to restore age-related NAD+ decline
• Mitochondrial-targeted antioxidants: MitoQ, MitoE for direct mitochondrial protection
• Cellular metabolism modulators: Targeting the metabolic intersection of aging and neurodegeneration
• Geroprotectors: Pharmacological interventions that target fundamental aging mechanisms (mTOR, AMPK, sirtuins)
• Young Blood Factors: Therapeutic plasma derived from young donors to restore cognitive function
• Epigenetic Reprogramming: Partial reprogramming using Yamanaka factors to reset cellular age

Key Entities

• [Neurons](/cell-types/neurons)
• [Microglia](/cell-types/microglia)
• [Astrocytes](/cell-types/astrocytes)
• [Mitochondria](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
• [Synapses](/mechanisms/synaptic-dysfunction)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [Proteostasis Network](/mechanisms/proteostasis-network)
• [Cellular Senescence](/mechanisms/cellular-senescence-alzheimers)
• [Neuroinflammation](/mechanisms/inflammaging-neurodegeneration)

See Also

• [Aging and Neurodegeneration](/mechanisms/aging-neurodegeneration)
• [Inflammaging in Neurodegeneration](/mechanisms/inflammaging-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS (Amyotrophic Lateral Sclerosis)](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Huntington's Disease](/diseases/huntingtons)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
• [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence-neurodegeneration)
• [Synaptic Dysfunction Hypothesis](/mechanisms/synaptic-dysfunction)
• [Proteostasis in Neurodegeneration](/mechanisms/proteostasis-neurodegeneration)
• [Protein Aggregation Disease Comparison](/mechanisms/protein-aggregation-disease-comparison)
• [Neuroinflammation Comparison](/mechanisms/neuroinflammation-comparison)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: TREM2
• [Selective HDAC3 Inhibition with Cognitive Enhancement](/hypothesis/h-0e675a41) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: HDAC3
• [Age-Dependent Complement C4b Upregulation Drives Synaptic Vulnerability in Hippocampal CA1 Neurons](/hypothesis/h-2f43b42f) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: C4B
• [Chromatin Accessibility Restoration via BRD4 Modulation](/hypothesis/h-addc0a61) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: BRD4
• [TET2-Mediated Demethylation Rejuvenation Therapy](/hypothesis/h-d7121bcc) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: TET2
• [Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration](/hypothesis/h-0e614ae4) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: SIRT3
• [HDAC3-Selective Inhibition for Clock Reset](/hypothesis/h-a9571dbb) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: HDAC3

Related Analyses:

• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-20260402) &#x1f504;
• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v2-20260402) &#x1f504;
• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v3-20260402) &#x1f504;
• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v4-20260402) &#x1f504;
• [Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v5-20260402) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Aging vs Neurodegeneration: Mechanistic Comparison Matrix discovered through SciDEX knowledge graph analysis: